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Mesenchymal stem/stromal cells (MSCs) are increasingly
used as an intravenously applied cellular therapeutic.
They were found to be potent in situations such as
tissue repair or severe inflammation. Still, data are
lacking with regard to the biodistribution of MSCs,
their cellular or molecular target structures, and the
mechanisms by which MSCs reach these targets. This
review discusses current hypotheses for how MSCs can
reach tissue sites. Both preclinical and clinical studies
using MSCs applied intravenously or intra-arterially are
discussed in the context of our current understanding of
how MSCs might work in physiological and pathological
situations.marker analysis. In a second study [6], these authorsBackground
In the 1970s, Friedenstein and colleagues [1] first reported
that locally applied culture-expanded populations of bone
marrow stroma-derived fibroblastic cells remained at their
injection sites under the kidney capsule, where an ectopic
hematopoiesis was initiated. Later, Arnold Caplan’s group
described mesenchymal stem/stromal cells (MSCs) as
multipotent mesenchymal cell populations which can
differentiate into several tissue types, and demonstrated
roles for MSCs in the regeneration of bone, cartilage or
ligaments in animal and clinical studies [2–4]. In these
studies, however, transplanted cells were followed, if at
all, at the site of transplantation, and biodistribution
was not an issue.
By the year 2000, clinicians had become increasingly
interested in intravenously applied MSCs. Pivotal studies
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stated.imperfecta, an inherited enzyme deficiency of collagen
synthesis by mesenchymal cells in bone, opened the field
for intravenous use of MSCs. This concept started from
the observation that bone marrow transplantation can
provide stromal cells able to synthesize intact collagen
type I, replacing deficient patient cell function and
ameliorating disease symptoms [5]. Therefore, the au-
thors concluded that transplantation of isolated healthy
allogeneic MSCs might cure the disease. This implies
homing of transplanted MSCs to sites in bone marrow
and/or bone. Efficacy was noted in all six infants treated
[5]. Children who received transplants showed improved
growth rates and started to synthesize intact bone. En-
graftment of donor-type MSC-derived osteoblasts was
shown using bone specimens and microsatellite DNA
showed that autologous, enzyme-deficient MSCs trans-
duced with a copy of the intact gene resulted in normal
collagen production in bone cavities. Moreover, children
who received transplants approached growth curves simi-
lar to the children transplanted with allogeneic complete
bone marrow [6]. This pioneering work provided the basis
for the successful application of MSCs using the intraven-
ous route in other clinical entities.Establishment of methods to track intravenously
administered MSCs
After 2000, the therapeutic use of MSCs by intravenous
administration was explored by a number of studies in
animals and also humans. These studies used various
ways to label culture-expanded MSCs, and to track them
in different tissues over time. The tissue source of the
MSCs was in most cases not decisive, and cells from
various tissue sources were explored. The labeling meth-
odologies used included radioactive labeling of MSCs,
labeling with fluorescent vital dyes, contrast agents,
transduction with reporter genes, or the use of donor
cell-specific DNA markers such as microsatellites [7–11]ss This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
u give appropriate credit to the original author(s) and the source, provide a link
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part, designed to detect only short-term homing of MSCs.
In addition, they do not enable the determination of
whether detected cells are still alive. These studies were
mainly conducted in rodents and nonhuman primates and
mostly in non-injury situations. The main common results
of these studies were that: MSCs distribute to a variety
of tissues after intravenous (i.v.) injection; MSCs are
detectable at low or very low frequencies in tissues
after transplantation; and signals from the injected cells
were found early after administration of the MSCs at
the highest frequencies in the lungs, followed by liver
and spleen.
The observed biodistribution patterns were confirmed
by studies in humans. In patients with mammary carcin-
oma, Koç et al. [13] demonstrated that i.v. MSCs were
well-tolerated in patients at a dose of one million MSCs/
kg body weight; however, the cells were trackable in
blood only. The data were confirmed in patients with
liver cirrhosis using 111In-oxine labeled MSCs, which
were found to first accumulate in the lungs followed by
continuous increases in liver and spleen up to day 10
after administration [14]. The proportion of accumulation
in lung decreased from about 35 % early after transplant-
ation to 2 % or less by day 10, whereas spleen had the
highest signals by day 10 after transplant. These results
confirm a similar overt biodistribution of MSCs in lung,
liver and spleen in humans to that observed in animal
models.
Expression of cell adhesion molecules by MSCs as
a basis for their interaction with endothelial cells
and tissue-directed extravasation
In theory, the main prerequisite for the interaction of
transplanted MSCs with endothelial cells are adhesion
molecules present on the cell surface of MSCs, and
expression of appropriate adhesion counter-receptors
on endothelial cells. MSCs (most investigations were
performed in human MSCs (hMSCs)) have shown deficits
in receptor binding to selectins and/or their ligands. They
lack expression of L-selectin, and their E-selectin ligand
(CD44) is not functional [15]. MSCs can bind to P-selectin
through a fucosylated ligand, which nevertheless is not P-
selectin glycoprotein ligand (PSGL)-1 [16]. Thankamony
and Sackstein [17] have, however, defined an enzymatic
fucosylation procedure which causes the CD44 epitope on
MSCs to strongly bind to endothelial E-selectin, resulting
in effective rolling of MSCs on endothelial cells and,
moreover, extravasation into bone marrow sites. Of the
integrins, alpha4beta1 (VLA-4) and alpha5beta1 (VLA-5)
have been found to be expressed by MSCs, whereas the
beta2 integrins alphaLbeta2 (LFA-1) and alphaMbeta2
(Mac1) could not be detected [15, 16, 18–20] (reviewed in
[12, 21]). Interestingly, several chemokine receptors havebeen found to be expressed on MSCs, including CXCR4,
which has been described as a major mediator of the
homing and mobilization of hematopoietic cell types
[12, 19, 20]. In summary, these findings indicate that
MSCs have a deficit with regard to the expressing and/
or employing adhesion receptors for coordinated ex-
travasation and tissue-specific homing, as do leukocyte
populations.
Emergence of common themes in exploring the
biodistribution of MSCs
Subsequent to the first reports on the homing and migra-
tion of transplanted MSCs to tissues, additional questions
about MSC biodistribution have been addressed, including
quantification of MSCs, their preferential homing to
several target sites, and the involvement of cues, such
as regeneration or inflammation, and the size of MSCs
in determining their biodistribution (Table 1).
In many of the earlier studies, the target sites as well
as the molecular mechanisms governing the interactions
of MSCs with the local environment after transplantation
(e.g., endothelial cells, target tissue), such as adhesion mol-
ecules or signaling mechanisms, were either not addressed
or were analyzed only to a minor degree. Moreover, MSCs
were often evaluated by microscopy, a method relatively
prone to artifacts. Many studies also did not quantify the
numbers of MSCs in target or other tissues. Likewise, only
few studies reported on the size of the identified MSCs.
Despite this lack of information, other themes have
emerged, especially research on cues that may regulate the
biodistribution of systemically applied MSCs; these in-
clude first pass tissues, specifically the lungs, inflamma-
tion, irradiation, sites of hypoxia or repair, and cancer
(Table 1). As a result, concepts have been raised which
imply an ability of MSCs to migrate to specific sites—e.g.,
MSCs as an “injury drugstore” for several acute clinical
situations [21, 22].
First-line accumulation of intravenously
administered MSCs in the lungs
The first hurdle for intravenously transplanted MSCs is
the lung capillary bed. After culture expansion, MSCs
are relatively large cells with an estimated average size of
around 30 μm in suspension (ranging from 16–53 μm)
[23]. Their size may also vary depending on the osmolarity
of the culture media, passage number, and/or cell density
during seeding as well as general culture conditions (two-
dimensional versus three-dimensional culture). In com-
parison with MSCs, hematopoietic stem cells have a much
smaller diameter, ranging from 4–12 μm depending on
the subfraction analyzed [24, 25]. Therefore, obstructive
events during lung passage are expected after intravenous
administration of MSCs. Lee et al. [26] presented a kinetic
study of MSCs accumulating in murine lungs in which up
Table 1 Common themes in MSC biodistribution research
Theme Targeted tissues (possible mechanism) References





Other (many) tissues [31]
Side effects of intra-arterial versus intravenous delivery? Incorporation into vessel wall [23, 35]
Obstruction of microvessels [38]
Vascular occlusion [39]
Targeting of vessel wall and vessel-associated tissues? Lungs, lymph nodes, intestine [47]
Targeting of tissues for regeneration Myocardium [18, 48–55]
Beta1 integrins [48, 49]
CCL2, monocytes [52]
Kidney [33, 56–63]





P/E selectin (CD44) [73]
CXCR4/flk-1/EPO-R [74]
Homing to bone marrow Bone marrow [76–81]
HCELL/E-selectin [15]
Subendothelial localization [79]





Prostaglandin E2 [37, 41]
Elimination mechanisms? Antibody formation [6]
Phagocytes [102]
Influence of radiation on homing? Increased in brain, heart, bone marrow, and muscles [43, 82]
Homing in malignancies? Tumor [83–85, 87–92]
Mediated by CCL25 [88]
Mediated by sodium iodide symporter under the control of
RANTES/CCL-5 promoter
[87]
Homed MSCs form tumor-associated fibroblasts [90]
Formation of microvesicles Microvesicles may contribute to/be part of MSC biodistribution [14, 63, 93–97]
Mediated by horizontal transfer of microRNAs [96]
MSC Mesenchymal stromal/stem cell
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few minutes after injection. Moreover, formation of emboli
in lung vessels was noted. The MSC signal (an Alu se-
quence DNA marker) fell exponentially, with a half-life of
about 24 h and practically complete disappearance after
4 days [26]. Barbash and colleagues [10] confirmed thedetection of the overall MSC load in the lungs using
99mTc-labeled MSCs in a rat model with induced myocar-
dial infarction. Murine MSCs also showed deleterious ef-
fects in mice, including post-injection lethality, which was
not the case after administration of hMSCs [27]. Inter-
action of human or murine MSCs with lung endothelial
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the transplanted cells were administered [27]. Adhesion of
the MSCs to endothelial cells was found to involve the in-
tegrin ligand vascular cell adhesion molecule (VCAM)-1.
When comparing MSCs with mononuclear cells from
bone marrow, neural stem cells and multipotent adult
progenitor cells, Fischer et al. [28] found that MSCs
showed the highest interaction with lung endothelia,
which could be inhibited by pretreatment with anti-
CD49d antibody. In a study by Kerkelä et al. [29], adhesion
of MSCs to lung tissue (probably endothelial cells) was
dependent on the enzyme treatment used during harvest-
ing of confluent MSCs in culture before transplantation;
after treatment with pronase, MSCs more readily cleared
the lungs and could be found in other tissues compared
with trypsinization treatment. Taken together, these data
indicate an active role of the adhesion molecules VLA-4/
VCAM-1 on MSCs/endothelial cells during interaction of
MSCs with lung tissue. It remains to be clarified, however,
whether this is a passive or active process. Also, relatively
little is known about possible adhesion molecules other
than VLA-4/VCAM-1 which may be operative in the
interaction of MSCs with endothelial cell surfaces in the
lung. This includes the fucosylation of CD44 to HCELL, a
highly active E-selectin ligand on MSCs, which is relevant
in bone marrow endothelia but seemingly did not affect
lung interactions [15].
In summary, presently there is strong evidence that ac-
cumulation of MSCs in the lungs is a key determining
factor for their biodistribution. The major adhesion
molecule involved seems to be VLA-4/VCAM1. Still, it is
not clear to what degree the findings in animal studies are
quantitatively transferable to humans (Table 1).
Biodistribution of MSCs after intra-arterial versus
intravenous administration
Studies comparing intra-arterial and intravenous appli-
cation of MSCs have demonstrated a major association
between intravenous application and retention of MSCs
in the lungs, and their increased accumulation in thera-
peutic target tissues after intra-arterial injection. Walczak
et al. [30] in a rat transient ischemia stroke model applied
two independent detection methods (magnetic resonance
imaging and Doppler flowmetry). They demonstrated that
higher cerebral engraftment rates are associated with im-
peded cerebral blood flow, and that intra-arterial delivery
may be advantageous in ischemic stroke to deliver MSCs
to the site of injury. Mäkelä et al. [31] compared intra-
arterial and intravenous administration of MSCs labeled
with 99mTc, and also found that the intra-arterial trans-
plantation route has a positive impact on the biodistri-
bution of bone marrow-derived MSCs (BM-MSCs) to
peripheral tissues. They found that intra-arterial trans-
plantation decreased the deposition of BM-MSCs in thelungs and increased uptake in other organs, especially
in the liver. In a study looking at human adipose tissue-
derived MSCs in SCID mice, Toupet et al. [32] showed
that 15 % of intra-arterially injected MSCs accumulate
in inflamed joints during the first month, and 1.5 %
over a longer term of >6 months, also favoring intra-
arterial over intravenous application for, in their case,
anti-inflammatory MSCs. Therapeutic effects of MSCs
in kidney have been generally achieved after intra-
arterial delivery [33, 34]. Although more studies will be
needed, these data suggest that the intra-arterial route
of administration is effective in avoiding pulmonary en-
trapment of BM-MSCs, and may thus improve the bio-
distribution and bioavailability of transplanted MSCs in
clinically relevant tissues for, e.g., tissue repair.
Interactions of MSCs with the blood vessel wall:
integration into the vessel wall or transmigration?
As described above, the majority of intravenously injected
MSCs are generally detected in the lungs, and in no other
tissue at comparable numbers even at later time points.
Some groups asked whether MSCs may directly target
vessels or perivascular tissue and investigated the fate of
MSCs in and around blood vessels. These studies followed
the cells using intravital microscopy and histologic exam-
ination in different tissues after intra-arterial [23, 30, 35]
administration. In the cremaster muscle intravital micros-
copy model, Furlani et al. [23] observed that the microcir-
culation was disturbed, with some MSCs obstructing
small vessels. In addition, pulmonary emboli were found.
Toma et al. [35] also observed occlusion of microvessels
and entrapment of the injected MSCs. Moreover, they ob-
served stable integration of some transplanted cells into
the vessel wall. Cui et al. [36] reported a risk of vascular
occlusion in their rat stroke infarction model after intra-
arterial injection, pointing to the fact that local intravasal
entrapment of MSCs may frequently occur, and MSCs
may obstruct the microcirculation. Currently, however, we
lack conclusive data that MSCs that are entrapped in
capillaries and/or are incorporated into the vessel wall
or adjacent to endothelial cells would relocate (i.e., “home”)
to their main tissue of origin, pericytes.
Transplanted MSCs interact with cells of the
immune system
Transplanted MSCs have been shown to rapidly interact
with immune cell types, which are—at least in part—
present also in the bloodstream. In a lung sepsis model,
Nemeth et al. [37] observed that MSCs co-localize with
lung-resident macrophage cells and induce them to pro-
duce anti-inflammatory interleukin (IL)-10 via release of
prostaglandin E by MSCs as part of their therapeutic ef-
fect. Chiesa et al. [38] showed that interstitial dendritic
cells (DCs) decrease their physiological migration from
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tion of MSCs. They describe that MSCs inhibit Toll-like re-
ceptor (TLR)-4-induced activation of DCs, which results in
the inhibition of cytokine secretion by DCs, downregulation
of adhesion molecules involved in the migration of DCs to
the lymph nodes, suppression of DC antigen presentation
to CD4+ T cells, and cross-presentation to CD8+ T cells.
Akiyama et al. [39] demonstrated that both human and
murine MSCs can induce immune suppression by attract-
ing and killing autoreactive T cells through FasL, thereby
stimulating transforming growth factor beta production
by macrophages and generation of regulatory T cells.
The interaction has been shown to involve the secretion
of MCP-1 by MSCs. The dying T cells in turn activate
macrophages to produce transforming growth factor beta,
thus stimulating regulatory T cells and promoting immune
tolerance. Possibly, the secretion of anti-inflammatory
protein TSG-6 by activated MSCs, which has been de-
scribed in a zymosan-induced mouse peritonitis model,
involves an interaction via TLR2/reduction of NF-κB
signaling in resident macrophages [40].
Another type of potential interaction between MSCs
and immune cells is suggested by data from Kim et al.
[41], who used an in vitro system showing that murine
MSCs inhibit functionality of DCs through TLR-4-
mediated signals in co-culture with monocytes. During
this study, hMSCs revealed a unique immunophenotype
of alternatively activated human monocytes which are
CD206-high, IL-10-high, IL-6-high, IL12-low, and
tumor necrosis factor (TNF)-alpha-low [42]. The im-
mune suppressive effects of MSCs have been shown to
depend on induction of indoleamine 2,3-dioxygenase
[43], or production of prostaglandin E2 as a main ef-
fector to dampen inflammation [37, 44]. These data
indirectly support the hypothesis that MSCs interact
directly with monocytic and/or antigen-presenting
cells in vivo.
The successful therapeutic use of MSCs in patients
with severe immune dysregulations, such as graft-versus-
host disease after allogeneic hematopoietic stem cell trans-
plantation, has attracted high interest by hematologists
(reviewed in [45]). The studies were based on a number of
in vitro findings that MSCs can either interact with or
affect the function of various types of immune effector
cells such as antigen-presenting cells, B or T lymphocytes,
or natural killer (NK) cells (reviewed in [46]). In all these
studies, identification of MSCs at target sites has been
cumbersome, and often no transplanted MSCs were iden-
tified. von Bahr et al. [47] reported that MSC donor DNA
was detectable at low levels in 8 out of 18 patients in
vessel-associated tissues in the patients, including lungs,
lymph nodes, and intestine. Detection of MSC donor
DNA was negatively correlated with time from infusion to
sample collection.Together, these studies strongly indicate the existence
of interactions between transplanted MSCs and cells of
the immune system. This way, MSCs also biodistribute
to the immune system through contact with different
types of leukocytes in the circulation or various tissues
such as skin, spleen, and lymph nodes.
Potential mechanisms of elimination of MSCs
from the circulation
A relevant aspect of the interaction between trans-
planted MSCs and immune system cells, in both animal
models and humans, is the induction of xenogeneic and
allogeneic immune responses, resulting in antibody for-
mation or T-cell responses against the transplanted
MSCs. Induction of antibody formation explains the
failure to identify transplanted MSCs in patients upon
repeated administration of allogeneic MSCs that had
been cultured in fetal bovine serum-containing media
[6]. Anti-fetal calf serum antibody formation has been
demonstrated in patients that did not respond to re-
peated MSC applications [6]. Elimination of xenogeneic
MSCs in some of the animal models studied may occur
in ways analogous to those in the allogeneic situation.
Despite the fact that several target tissues of MSCs
have been established, there are few data as to the place
to which systemically applied MSCs will finally migrate,
or where they end up before or when they are elimi-
nated. The fact that the transplanted MSCs are often not
detectable at all, or only a small fraction of them is
traced, underscores the potential relevance of the lung
as a “first pass” tissue, and may indicate an involvement
of lung trapping in elimination of MSCs. On the other
hand, the fact that MSCs are barely or not at all detect-
able in patients after transplantation demonstrates that
systemic pathways to eliminate transplanted MSCs may
be operating in humans, leading to barely detectable
long-term engraftment.
Tissue repair situations which provide cues to
attract transplanted MSCs
The interactions of MSCs with different types of immune
cells point to their ability to respond to signals from the
immune system. Since aspects of tissue repair have been
associated with (adaptive) immune responses, it is likely
that inflammatory and tissue repair signals influence MSC
responses in vivo, including their biodistribution.
Myocardial infarction
The VLA-4/VCAM receptor axis has been shown to be
involved in MSC migration in myocardial infarction.
Pre-treatment of MSCs with TNF-1alpha stimulated
migration of MSCs through heart endothelia mediated
through VCAM-1, indicating that beta1 integrins are
actively involved in this process [48]. Confirming this
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model that alpha4 integrin is required for migration of
MSCs to myocardium, whereas the chemokine receptor
CXCR4 was dispensable for the entry of transplanted
cells into ischemic tissue.
Intravenously administered MSCs have been observed
to, at least transiently, accumulate in areas of myocardial
ischemia [18, 50, 51]. To this end, Belema-Bedada et al.
[52] employed a transgenic mouse model expressing the
monokine CC-chemokine ligand (CCL)2 under a cardiac
specific promotor, increasing CCL2 expression in heart
muscle. These authors observed that i.v. MSCs accumu-
late rapidly and selectively in the heart. They showed
that the migration of the MSCs to heart is preceded by
monocyte emigration to the myocardium, and involves
G-protein-coupled receptors, pointing also towards the
involvement of chemokine signals. Kraitchman et al. [11]
confirmed the accumulation of i.v. MSCs into myocardial
infarction areas using a radioimaging tracer and single-
photon emission computed tomography in a dog model.
Wang et al. [53] traced MSCs at later stages after infarction,
and saw markers of newly regenerated cardiomyocytes. It is
also not clear whether MSCs steadily incorporate into car-
diac tissue. Other studies have failed to detect any homed
MSCs in cardiac tissue over the long term (e.g., [54]).
Jasmin et al. [55] injected MSCs i.v. after nanoparticle
labeling in a model of heart inflammation caused by
the Chagas disease parasite Trypanosoma cruzi. They
observed that although most MSCs migrated to the
lungs, liver and spleen, a few cells homed to the in-
flamed heart. In conclusion, some mechanisms seem to
recruit, mostly transiently, some MSCs to inflamed or
ischemic heart, including VLA-4/VCAM-1 and the CCL2
and possibly other chemokine receptor signals.Kidney damage
Despite the wide range of beneficial effects seen with the
therapeutic use of MSCs in animal models, only a few
clinical trials have tested the efficacy of MSCs for renal
diseases. Reinders and colleagues [56] used intravenous
injection of 1 × 106 autologous BM-MSCs/kg in six kid-
ney allograft recipients to dampen rejection of the graft
and/or decrease interstitial fibrosis and tubular atrophy.
Likewise, Tan et al. investigated autologous BM-MSCs
(1–2 × 106/kg) at kidney reperfusion and 2 weeks after
application; the incidence of acute rejection decreased
and renal function at 1 year improved compared with
anti-IL-2 receptor antibody induction therapy [57]. In a
clinical phase I safety trial, five patients aged >65 years
with underlying renal disease and multiple comorbidities
were infused with allogenic MSCs during coronary artery
bypass or cardiac surgery. Although the follow-up period
was short and one of the patients died, none of the patientsrequired dialysis, supporting the beneficial influence of
MSCs on repair of kidney damage [58, 59].
In animal studies, MSCs were also associated with re-
pair of the permeability barrier of the glomerulus in an
Alport disease model [60] and improved kidney function
in an experimental sepsis mouse model through repro-
gramming of macrophages via release of prostaglandin
E2 [37]. Morigi and colleagues [61, 62] have shown that
treatment with murine BM-MSCs (2 × 105 per mouse) in
an acute renal failure mouse model induced by cisplatin
(a nephrotoxic anti-cancer drug) protected the animals
from renal function impairment and tubular injury. In-
triguingly, the effects of MSCs in stimulating prolifera-
tion and inhibiting apoptosis of tubular epithelial cells in
a glycerol-induced acute kidney injury SCID mouse model
could also be achieved by using microvesicles derived
from hMSCs [63]. In addition to these human studies, sev-
eral studies demonstrate that MSCs localize within injured
kidneys when injected in mice with acute kidney injury
(e.g., [34, 63]; reviewed in [58]). The presence of MSCs at
later stages of kidney injury or regeneration has not been
studied, but the therapeutic benefits have been measured,
and intra-arterial injection of MSCs seems to be more
favorable [33, 34, 61].
Liver damage
Gholamrezanezhad et al. [14] studied i.v. infused 111In-
oxine-labeled MSCs in patients with liver cirrhosis. The
radioactivity was first observed to accumulate in the
lungs. During the following hours to days, the radio-
activity gradually increased in the liver and spleen, with
spleen uptake exceeding that in the liver in all patients.
In the liver and spleen, radioactivity increased by day
10 post-infusion, whereas residual activity in the lungs
decreased approximately tenfold. In contrast, Briquet
et al. [64] saw no recruitment of hMSCs to liver dam-
aged by CCl4 intoxication in immune-deficient mice. A
study by Zhang et al. [65] indicates that corticosteroids
and the SDF-1/CXCR4 axis are involved in MSC migra-
tion in a carbon tetrachloride-induced liver fibrosis model.
Another liver regeneration model in mice indicated that
MSC homing to liver was associated with regeneration,
but the mechanisms for this were not investigated [66].
In summary, although many of the published studies
have not addressed aspects of MSC biodistribution,
there is some evidence for biodistribution to injured or
diseased livers, but the underlying mechanisms are
mostly unclear.
Gut and skin
Only a few studies have analyzed MSC accumulation in
epithelial tissues so far. Inflammatory bowel disease
models have addressed homing of i.v. MSCs. Parekaddan
et al. [67] demonstrated the presence of MSC-derived
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of affected animals. Sasaki et al. [44] assessed whether
homed MSCs can differentiate into skin cells, including
keratinocytes, and whether they could contribute to wound
repair. They i.v. injected green fluorescence protein (GFP)
transgenic MSCs and identified GFP-positive cells associ-
ated with specific markers for keratinocytes, endothelial
cells, and pericytes. They attribute the extravasation to
inflamed areas to the presence of the chemokine CCL21
in vessels in the inflamed tissue. Still, numbers of detected
MSCs in the wounded skin areas were low. MSCs have
been found in wound tissues several days after trans-
plantation in animal models [68–71] but their engraft-
ment efficiency ranged from <0.01 % when MSCs were
intravenously injected to 3.5 % in a study where MSCs
were locally applied. This points to a minor role of i.v.
injected MSCs in skin repair. One study reported that,
after intravenous injection of GFP transgenic MSCs,
keratinocytes, endothelial cells, pericytes and macro-
phages within the healed wound were all found to be
GFP-positive. The authors concluded that they might
be derived from donor MSCs [71].Brain
Some studies have investigated whether transplanted MSCs
migrate into inflamed brain tissue. In murine stroke
models, MSCs migrated into ischemic areas after intra-
venous delivery [72, 73]. The latter study mentions that
the MSCs are recruited to these sites via endothelial
expressed P- and E-selectin, and that CD44 is present
on the MSCs. In their rat brain ischemia model, Wei et al.
[74] found that i.v. MSCs localize to ischemic zones and
deliver neurotrophic factors. This occurs at an increased
rate when MSCs have been exposed to hypoxia before
transplantation. The extravasation efficiency of the MSCs
correlated with increased expression of CXCR4, flk-1 and
the erythropoietin receptors, and downregulation of pro-
inflammmatory regulators in the homing MSCs. The ac-
tivity of microglia formation was suppressed in animals
after MSC therapy, and NeuN-positive and Glut1-positive
cells were increased. Constantin et al. [75] used intravital
microscopy in a murine experimental autoimmune en-
cephalitis model. They found, using bioluminescence,
accumulation of a subset of transplanted MSCs in in-
flamed brain venules in inflammatory foci of experimental
autoimmune encephalomyelitis 16 and 30 days after
transplantation, and showed a role for alpha4 integrin
in the migration process of MSCs into brain tissue. Al-
though absolute numbers of transplanted MSCs were
not determined and may be low, the results indicate
that active inflammation may switch the homing behavior
of transplanted MSCs from unspecific entrapment to
specific recruitment.Together, these data indicate that MSCs can migrate
into ischemic and proinflammatory regions in certain
disease models. Mostly short- (within the first 3 days)
and mid-term (3 days to 3 months) homing has been re-
ported, whereas long-term persistence (>3 months) of
MSCs is rarely detected. Due to the technologies used to
detect transplanted cells, there is only limited evidence
to indicate whether the MSCs home as intact cells into
their target environments. The data are in favor of tran-
sient homing and locally acting MSCs in the investigated
pathologies.Homing of transplanted MSCs to bone marrow
Several decades of clinical and experimental work in
the field of bone marrow transplantation have shown
that donor type MSCs will generally not engraft in
allogeneic hosts, including the precursor cell type for
MSCs, fibroblast colony-forming units [76–78]. Rombouts
and Ploemacher [79] demonstrated that prolonged time
in culture induces a defect in MSCs that affects their
engraftment into bone marrow in a classic bone mar-
row transplantation situation. In contrast, as reported
above, Horwitz and colleagues [5, 6] demonstrated that
MSCs engraft into bone marrow of children with osteo-
genesis imperfecta. Possibly, engraftment of MSCs
therefore requires a “niche” which is not free in normal
bone marrow transplant recipients, but is created in a
deficiency state such as the collagen synthase defect
found in osteogenesis imperfecta. Follenzi et al. [80]
recently demonstrated that mice suffering from hemophilia
A, when transplanted with normal healthy total bone
marrow cells, show engraftment not only of hematopoietic
cells but also of subendothelial MSC-like cells. Interest-
ingly, these MSCs had not been cultured before trans-
plantation. Functional MSCs may, therefore, engraft, at
least in the case of certain deficiencies in the transplanted
hosts. Interestingly, the group of Horwitz more recently
showed that non-plastic-adherent bone marrow cells en-
graft in a murine model and give rise to osteoprogenitors,
which are more potent osteoprogenitors than “classic”
plastic-adherent MSCs in mice [81]. This underscores the
possibility that the culture period induces the engraftment
defect, and that, in addition, cells other than “classic”
MSCs can mediate stromal engraftment. On the other
hand, “classic” plastic-adherent MSCs have been shown to
remain as a source of hematopoietic environment when
transplanted into tissues other than bone marrow [1]. In
contrast to these findings, the model by Sackstein et al.
[15], where an active E-selectin ligand was engineered on
the surface of plastic-adherent MSCs, resulted in efficient
homing to bone marrow, indicating the possibility of
BM-MSCs (or MSCs from other tissue sources) distributing
to bone marrow.
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biodistribution of MSCs
In a murine study, Francois et al. [43] showed that both
total body irradiation and local irradiation (e.g., selective
irradiation of abdomen or legs) affected the distribution
of i.v. infused hMSCs in NOD/SCID mice compared
with untreated animals. Intravenously infused hMSCs were
found only in minimal amounts exclusively in the lung,
bone marrow, and muscles in non-irradiated control
animals. Mice after total body irradiation had increased
absolute numbers of hMSCs in brain, heart, bone marrow,
and muscles. Moreover, selective radiation of limbs or the
abdomen yielded increased engraftment of hMSCs in the
exposed skin or muscles than with total body irradiation
alone. hMSC engraftment outside the locally irradiated re-
gions was also increased, pointing to both local and sys-
temic effects of irradiation on MSC engraftment. The
study did not investigate long-term engraftment. Sémont
et al. [82] looked at the engraftment and efficacy of trans-
planted MSCs in an immunodeficient mouse model of
radiation-induced gastrointestinal tract failure. They dem-
onstrated accelerated recovery in the group receiving
hMSCs, with decreased apoptosis of epithelial cells and in-
creased proliferation within the small intestinal mucosa.
Yet, transplanted MSCs were not detected at significant
amounts.
A special case: migration and engraftment of
MSCs into tumors
Tumor-associated fibroblasts have been described as a
form of MSCs, which are recruited from the MSC pool and
are an integral part of the microenvironment of many dif-
ferent solid tumors [83, 84]. Tumor tissue therefore also
represents a target for the homing of i.v. injected MSCs. In
experimental studies, both beneficial and adverse effects
have been reported. Beckermann et al. [85] verified the mi-
gration of i.v. MSCs into areas close to the vessel wall in
human pancreatic tumors in immunodeficient mice. Alieva
et al. [86] followed locally implanted adipose tissue-derived
MSCs with a genetic modification induced by lentiviral
transduction and traced them by bioluminescence in a glio-
blastoma model. After incorporation of the transplanted
MSCs, administration of gancyclovir activates the thymi-
dine kinase transgene, resulting in death and elimination of
the transplanted MSCs and tumor regression. A PECAM-
Promotor-driven second transgene as reporter construct
served to indicate that the transplanted MSCs can acquire
endothelial-like characteristics. Similarly, Knoop et al. [87]
used i.v. MSCs expressing sodium iodide symporter under
the control of the RANTES/CCL-5 promoter; when loaded
with 131I compound these conferred significant anti-tumor
effects.
Xu et al. [88], in a myeloma model, showed that MSCs
are chemoattracted by the chemokine CCL25, thussupporting myeloma growth. In a Ewing sarcoma nude
mouse model, i.v. injected MSCs expressing IL-12 were
effective in treating the sarcomas [89]. Interestingly, the
transplanted MSCs themselves were not identified, while
the secreted IL-12 was. Kidd et al. [90] showed that
tumor-associated fibroblasts originating from transplanted
MSCs in syngeneic ovarian and breast cancers are re-
cruited from the bone marrow, whereas the bulk of
the vascular and fibrovascular stromal cells (pericytes,
α-smooth muscle actin-positive myofibroblasts, and
endothelial cells) were recruited from adipose tissue.
These data indicate a process whereby, once bone
marrow homing of transplanted MSCs is established,
these MSCs may be (genetically) directed along pre-
established pathways of endogenous MSCs that circu-
late from bone marrow to the tumor. Further work by
Grisendi et al. [91] demonstrated that the process of
MSC incorporation into tumors implies the formation
of epithelial–mesenchymal or endothelial–mesenchymal
transitions, and requires the formation of fibroblasts
derived from mesenchymal progenitors.
MSCs were also found to enhance angiogenesis, as
shown in models of B16 melanoma cells and Lewis lung
carcinoma [92]. Co-injection of tumor cells and MSCs
led to increased tumor size compared with injection of
tumor cells alone. Tumor vessel areas were greater in
tumors after co-injection of tumor cells with MSCs than
in tumors induced by injection of cancer cells alone. Co-
injected MSCs localized close to vascular walls, and also
expressed the endothelial marker CD31/PECAM-1.
In conclusion, MSCs show a clear tumor tropism.
Many data indicate that they are incorporated into the
tumor microenvironment and can stimulate tumor growth.
Their biodistribution and tumor tropism, however, may
also be exploited to target tumors, e.g., using a suicide
transgene approach.Recent developments: exosomes, microparticles
and MSCs
As with many other cell types, MSCs are capable of
forming exosomes [63, 93, 94]. Exosomes are small
membrane vesicles (40–100 nm in diameter) of endoso-
mal origin derived from MSCs. Exosomes have been
found to accumulate in target cells of MSC therapy, such
as tubular cells in acute kidney injury [63], or after re-
covery from traumatic brain injury [95]. In other studies,
microvesicles have been found to contain signaling mol-
ecules which are hypothesized to be important for MSC-
mediated therapeutic effects by horizontal transfer, such
as miR-133b in a rodent stroke model [96], or insulin-
like growth factor receptor in renal tubular injury [97].
Kordelas et al. [98] administered exosomes isolated from
MSCs to a patient with severe graft-versus-host disease; this
Leibacher and Henschler Stem Cell Research & Therapy  (2016) 7:7 Page 9 of 12patient showed marked improvement after the exosome
infusion. This field is currently expanding rapidly, and
can only be covered briefly by this review. One of the
relevant open questions for the biodistribution of MSCs
is whether exosomes are indeed formed by intravasally
administered MSCs.Summary: possible ways for MSCs to interact
within the local environment of the bloodstream
to direct their biodistribution
A summary of the possible ways MSC might interact
within the blood circulation is shown in Fig. 1. MSC sur-
face marker profiling has revealed no expression of the
co-stimulatory molecules CD40, CD86, and CD80 needed
for correct T-cell responses leading to T-cell anergy. In
vitro studies also showed that CD4+ T cells in contact
with MSCs were arrested in the G1/G0 phase and stopped
proliferating whereas regulatory T cell proliferation was
favored and IgG production by plasma cells seemed to
be affected [46]. In addition, MSCs only express a lowFig. 1 Possible ways that MSCs interact within the local environment of th
possible interactions are circled in green. APC antigen-presenting cell, EC en
IFN interferon, MHC major histocompatibility complex, MSC mesenchymal samount of major histocompatibility complex (MHC) I and
almost no MHC II (except after interferon-γ treatment),
making them more evasive to NK cell cytoxicity in an allo-
genic/xenogenic setting. Interactions between NK cells
and MSCs in general have been controversial, as discussed
by different groups (e.g., [99–101]). MSCs seem to lower
NK cell cytoxicity through downregulation of interferon-γ
expression and production of anti-inflammatory IL-4 and
IL 10, but NK cells were associated with the ability to lyse
MSCs from allogenic donors [99]. Additionally, the
so-called instant blood-mediated inflammatory response
might be triggered by the innate immune response caused
by tropism of dying MSCs within the blood circulation,
resulting in complement activation and opsonization of
injected MSCs following uptake of marked MSC cell frag-
ments by primary/secondary phagocytes, as was shown by
Moll et al. [102]. Intravital microscopy of MSCs in a
cremaster muscle mouse model (our unpublished data)
revealed that MSCs are likely to be disrupted by the
shear force of the blood flow, resulting in fragmentation of
the cell and creation of small extracellular vesicles able toe bloodstream. Descriptions of cell types are shown below and the
dothelial cell, IBMIR instant blood mediated inflammatory response,
tem/stromal cell, NK natural killer, Treg regulatory T cell
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molecules or cause phagocytosis of these fragments by
macrophages and endothelial cells, subsequently followed
by clearance of disrupted MSCs in the liver and spleen
within a few days. MSCs that find a niche and survived
the journey through the bloodstream might interact
actively or passively with the endothelial wall and may
extravasate after interacting with the extracellular
matrix (e.g., with MMP 2 and gelatinase) and reside in
a pericyte-like location in the long term.Conclusion
The final fate of the bulk of i.v. injected MSCs remains
elusive, since preclinical animal studies and some human
data have been able to detect only small proportions, if
any, of injected MSCs. A number of open questions re-
main. These include: Which contacts are made between
MSCs and other cells upon infusion in the bloodstream
and what are the consequences of these? What is the
fate of MSCs that do not migrate into inflamed tissue
and are there physiological clearance pathways for trans-
planted MSCs? Given that many therapeutic effects have
been observed without detectable MSCs in the target tis-
sues, are intact MSCs therefore relevant for the observed
effects?
We believe that further careful analysis of animal disease
models, including investigation of the role of mediators
such as exosomes, signaling proteins, and microRNAs, will
help further advance our understanding of why we have so
far not obtained clear answers about how MSCs biodistri-
bute, migrate and home, and how these cells exert their
beneficial effects, and what might be the potential of these
new insights for the development of further improvements
of MSC-derived therapies.Note: This article is part of a thematic series ‘Mesenchymal
Stem/Stromal Cells—An update’. Other articles in this series can
be found at http://www.biomedcentral.com/series/mesenchymalAbbreviations
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